Roche Makes Tocilizumab Launch Prediction As Biosimilars Progress
One Analyst Suggests: ‘There Have Been Filings’
Roche gave small insight into its expectations around biosimilar competition for its Actemra/RoActemra (tocilizumab) treatment for inflammatory diseases. Extraordinary demand for the biologic led sales to skyrocket by 143% in the third quarter and caused supply constraints for the originator.
